PHAT

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

04/13 01:00 pm

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

01/08 09:41 am

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

01/07 11:33 pm

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

10/23 08:00 am

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

10/20 08:00 am

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

08/20 08:00 am

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

07/28 08:00 am

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

04/16 08:00 am

Phathom Pharmaceuticals Announces Leadership Succession

04/01 08:00 am

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

03/06 09:00 am

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

01/29 09:00 am

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

10/28 08:00 am

The Top 3 Most-Shorted Stocks in August

08/21 03:16 pm

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08/08 08:00 am

Wall Street Breakfast: The Week Ahead

06/23 06:52 am

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

05/28 08:00 am

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates

05/09 09:15 am

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

04/03 08:00 am

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

03/26 08:00 am

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

03/07 09:00 am

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

02/29 09:00 am

Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

02/20 11:26 am

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01/31 09:00 am

"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

01/05 02:52 pm

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

12/06 09:00 am

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

11/28 09:00 am

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

11/01 05:00 pm

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

10/30 08:00 am

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

10/25 08:01 am

Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'

10/13 08:55 am

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

09/26 08:01 am

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

09/05 08:00 am

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

08/21 08:00 am

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

08/10 08:01 am

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023

08/09 11:00 am

Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies

07/10 08:26 am

3 Top Breakout Stocks Worth a Buy for Attractive Returns

07/07 08:38 am

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

06/12 08:01 am

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

06/09 04:01 pm

Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?

06/01 09:55 am

Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

05/26 09:55 am

Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?

05/25 09:55 am

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

05/23 07:41 pm

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

05/23 04:01 pm

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

05/23 04:00 pm

Analyst Expectations for Phathom Pharmaceuticals's Future

05/11 01:00 pm

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023

05/11 11:00 am

Phathom Pharmaceuticals Reports First Quarter 2023 Results

05/10 08:00 am

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

05/09 08:00 am

Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks

04/12 07:57 am